XASX
ATX
Market cap72mUSD
Jul 18, Last price
0.29AUD
1D
5.56%
1Q
448.08%
Jan 2017
-97.19%
IPO
-83.58%
Name
Amplia Therapeutics Ltd
Chart & Performance
P/E
—
P/S
24.88
EPS
—
Div Yield, %
—
Shrs. gr., 5y
34.89%
Rev. gr., 5y
144.97%
Revenues
4m
+274.34%
Net income
-5m
L-27.86%
CFO
-5m
L-3.07%
Profile
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
IPO date
Dec 23, 2013
Employees
1
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 4,453 274.34% | 1,189 -40.03% | |||||||
Cost of revenue | 8,937 | 7,475 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,484) | (6,286) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,438) | (1,148) | |||||||
Tax Rate | |||||||||
NOPAT | (46) | (5,137) | |||||||
Net income | (4,503) -27.86% | (6,242) 71.30% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 241 | 21 | |||||||
BB yield | 0.00% | -0.13% | |||||||
| Debt | |||||||||
Debt current | 1,573 | 2,181 | |||||||
Long-term debt | 109 | 189 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 9 | 4 | |||||||
Net debt | (1,704) | (6,886) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (5,127) | (5,290) | |||||||
CAPEX | (2) | (18) | |||||||
Cash from investing activities | (2) | (58) | |||||||
Cash from financing activities | (773) | (84) | |||||||
FCF | (817) | (4,598) | |||||||
| Balance | |||||||||
Cash | 3,385 | 9,257 | |||||||
Long term investments | |||||||||
Excess cash | 3,163 | 9,197 | |||||||
Stockholders' equity | 11,418 | 15,836 | |||||||
Invested Capital | 9,852 | 8,918 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 194,006 | 193,975 | |||||||
Price | 0.08 -9.41% | 0.09 -41.38% | |||||||
Market cap | 14,938 -9.40% | 16,488 -21.88% | |||||||
EV | 13,234 | 9,602 | |||||||
EBITDA | (4,398) | (6,212) | |||||||
EV/EBITDA | |||||||||
Interest | 78 | 54 | |||||||
Interest/NOPBT | |||||||||